Guide · Intellectual Property
Patents in Canada
Canadian patent law rewards early, careful filing and punishes gaps in ownership. This guide covers patentability, prosecution at CIPO, the new patent term adjustment, supplementary protection for drugs, the PM(NOC) regime and enforcement in the Federal Court, with the statutory provisions behind each rule.
Key takeaways
- A Canadian patent lasts 20 years from filing under s. 44 of the Patent Act.
- Applicants get a one-year grace period for their own disclosures, but other countries may not.
- Patent term adjustment under s. 46.1 applies to applications filed on or after 1 December 2020.
- Certificates of supplementary protection add up to two years for eligible drug patents.
- PM(NOC) actions must start within 45 days and trigger a 24-month stay.
- Methods of medical treatment are not patentable, as confirmed in 2026 SCC 26.
Patent law in Canada at a glance
Canadian patent law gives an inventor, or the inventor's assignee, a time-limited monopoly over a new, useful and non-obvious invention in exchange for public disclosure. The governing statute is the federal Patent Act, administered by the Canadian Intellectual Property Office (CIPO) and enforced mainly in the Federal Court. Patents are an exclusively federal matter under the Constitution Act, 1867, so the same rules apply in every province and territory, including Quebec.

For most businesses the practical questions are short: Is the invention patentable in Canada? When must we file to avoid losing rights through our own disclosures? How long will protection last, and can it be extended? And, for pharmaceutical companies, how do the linkage regulations and data protection rules interact with the patent? This page answers those questions and points to the provisions that matter.
| Feature | Canadian rule | Source |
|---|---|---|
| Basic term | 20 years from the filing date (applications filed on or after 1 October 1989) | Patent Act, s. 44 |
| Applicant's own disclosures | One-year grace period before the filing date | s. 28.2(1)(a) |
| Request for examination | Within four years after the filing date (non-divisional applications) | Patent Rules |
| Patent term adjustment | Additional term for unreasonable CIPO delay; filing date on or after 1 December 2020 | s. 46.1 |
| Certificate of supplementary protection | Up to two years for eligible drug patents | s. 116(3) |
| Look-back for damages | No remedy for acts more than six years before the action | s. 55.01 |
What Canadian patent law protects
Section 2 of the Patent Act defines an invention as any new and useful art, process, machine, manufacture or composition of matter, or any new and useful improvement of one. Three requirements follow: novelty, utility and non-obviousness (inventive ingenuity). The Act also excludes certain subject-matter outright. Section 27(8) provides that no patent may be granted for a mere scientific principle or abstract theorem.
Novelty and obviousness
Novelty is assessed under s. 28.2 against disclosures made before the claim date, subject to the applicant's one-year grace period. Obviousness is assessed under s. 28.3 from the perspective of a person skilled in the art on the claim date. Courts ask what the inventive concept of the claim is, how it differs from the state of the art, and whether bridging that difference would have required any inventive ingenuity. In practice, contemporaneous laboratory notebooks, records of failed approaches and evidence of the problem the inventors faced are often decisive. Businesses that keep disciplined research records are better placed both to obtain a patent and to defend it.
Utility after the promise doctrine
For years, Canadian courts applied a "promise of the patent" doctrine that could invalidate a patent if any promised use was not demonstrated or soundly predicted. The Supreme Court of Canada rejected that approach in AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36. Utility now requires a single use related to the subject-matter that was demonstrated or soundly predicted at the filing date. That decision reduced a significant validity risk for life sciences patentees.
Methods of medical treatment and computer-implemented inventions
Two categories need special care. First, methods of medical treatment are not patentable in Canada; the Supreme Court confirmed this in Pharmascience Inc. v. Janssen Inc., 2026 SCC 26 (17 July 2026). Claims should therefore be drafted as products, uses or compositions rather than as steps a physician performs. Second, computer-implemented inventions are patentable when the claimed invention, read purposively, is more than an abstract algorithm or a mere scientific principle. CIPO examines these claims closely, and drafting that ties the algorithm to a concrete technical solution remains important.
Filing strategy and prosecution at CIPO
Canada is a first-to-file jurisdiction. Priority goes to the earliest claim date, which is the Canadian filing date or a validly claimed Paris Convention priority date within 12 months. Most foreign applicants enter Canada through the Patent Cooperation Treaty (PCT) national phase.
The one-year grace period
Section 28.2(1)(a) gives applicants a one-year grace period for their own disclosures and for disclosures by people who learned of the invention from them. This is narrower than it first appears. Third-party disclosures before the claim date still count as prior art, and many other countries do not offer the same grace period. A business that publishes first and files later may keep Canadian rights but lose rights elsewhere.
Examination, excess claims and continued examination
Examination is not automatic. Under the Patent Rules, a request for examination must be made within four years after the filing date for an ordinary application. Since the 2022 amendments to the rules, an additional fee is payable for each claim in excess of 20 at the time of the request. If CIPO has sent several office actions without allowing the application, the examiner will require a request for continued examination (RCE) and a further fee before examination continues. Planning claim sets and responses with these costs in mind can save money and time.
- Before filing: confirm ownership through inventor assignments and employment terms, and check freedom to operate.
- At filing: decide whether a Canadian first filing, a PCT route or a Paris Convention filing best fits the commercial timetable.
- During examination: consider the Patent Prosecution Highway where a corresponding application has been allowed elsewhere, and manage claim counts.
- After grant: diarize maintenance fees, which are payable to keep the patent in force.
Patent term adjustment and supplementary protection
Patent law in Canada now contains two separate mechanisms that can extend protection beyond 20 years. They have different purposes and different conditions.
Patent term adjustment (additional term)
To meet a commitment under the Canada–United States–Mexico Agreement (CUSMA), Parliament added sections 46.1 to 46.3 to the Patent Act. Under s. 46.1, the Commissioner must grant an additional term where the patent issued after the later of five years from the applicable filing date and three years from the request for examination, the filing date is on or after 1 December 2020, and the patentee applies and pays the fee within three months after the patent is issued. The length of the additional term reflects CIPO delay, after the regulations subtract periods attributable to the applicant. Maintenance fees under s. 46.2 must be paid to keep the additional term in effect.
Certificates of supplementary protection
Certificates of supplementary protection (CSPs) were introduced after the Canada–European Union Comprehensive Economic and Trade Agreement (CETA). A CSP covers a medicinal ingredient or combination protected by an eligible patent and approved by Health Canada. Under s. 116(3), the term is the period from the patent filing date to the date of the drug authorization, minus five years, capped at two years. The certificate takes effect only when the patent term expires, and it is subject to a timely application.
The three-month window to apply for an additional term under s. 46.1(1)(c) runs from the day the patent is issued. Add it to the docket when you receive the notice of allowance, not after grant, and keep a record of every period of applicant delay so you can check CIPO's calculation.
Pharmaceutical patents: PM(NOC) and data protection
Patent law for pharmaceuticals in Canada is shaped by the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations). A generic or biosimilar manufacturer that refers to an innovator's drug must address patents listed on Health Canada's Patent Register. When the innovator, or "first person", receives a notice of allegation, it has 45 days to bring an action in the Federal Court under s. 6(1) for a declaration of infringement.
Starting that action triggers a stay on the generic's notice of compliance. Under s. 7(1)(d), the Minister may not issue the notice of compliance before the end of the 24-month period that begins when the action is brought, unless the action ends earlier. Since the 2017 reforms, these are full actions with discovery and a trial, and the outcome binds the parties on infringement and validity.
Separate from patents, the Food and Drug Regulations (s. C.08.004.1) provide data protection for innovative drugs. A subsequent manufacturer cannot file an abbreviated submission that relies on the innovator's data until six years after the innovator's first notice of compliance. Health Canada cannot approve that submission until eight years have passed, extended to eight years and six months where qualifying pediatric studies were provided.
Drug pricing
Patented medicines are also subject to price review by the Patented Medicine Prices Review Board (PMPRB). Pricing is a separate regulatory track, but a patent listing and a PMPRB filing usually need to be coordinated.
Ownership, privilege and patent transactions
Canadian patent law does not contain a general rule vesting employee inventions in the employer. Ownership depends on the contract and, absent clear terms, on the circumstances of the employment. Employment agreements, contractor agreements and research collaboration agreements should therefore contain written assignments and cooperation obligations.
Since 2016, communications between a patent agent and a client are privileged under s. 16.1 of the Patent Act if they are confidential and made to seek or give advice on patentability or other matters within the agent's role. That privilege is similar to solicitor-client privilege, but it attaches to registered patent agents. Only a registered patent agent may prosecute applications before CIPO for others; we coordinate with registered agents where that is required.
Patents in M&A and financing
In acquisitions, investors expect chain-of-title evidence, recorded assignments, maintenance fee status and a review of licences and security interests. Assignments of patents should be registered with CIPO. Security over patents is usually taken under provincial personal property security legislation, and in Quebec as a movable hypothec, with notice recorded at CIPO as a practical safeguard. Portfolios that include standard-essential patents need specific diligence, because s. 52.1 provides that a licensing commitment on a standard-essential patent binds any subsequent patentee.
Licensing terms that matter in Canada
A Canadian patent licence is a contract governed by provincial law, so the usual choices about governing law, exclusivity, field of use, sublicensing and improvements apply. A few points are specific to patent law in Canada. Exclusive licensees can generally sue for infringement as persons "claiming under" the patentee, so the licence should say who controls litigation and who bears its cost. Royalties paid to non-residents may attract Part XIII withholding tax under the Income Tax Act unless reduced by treaty. Licences between competitors can raise issues under the Competition Act, especially where they restrict output or territories. And in Quebec, a licence is governed by the Civil Code, which may affect implied warranties and termination rights.
Demand letters
Businesses that receive aggressive patent demand letters have a statutory tool. Section 76.2 of the Patent Act requires written demands relating to a patented invention to meet prescribed requirements, and a person who receives a non-compliant demand may apply to the Federal Court for relief. A recipient should keep the letter, avoid admissions, and assess both the patent and the demand before responding. A patentee sending a demand should check that it identifies the patent and the alleged infringing activity with enough precision to comply.
Enforcing and challenging patents
Infringement actions are usually brought in the Federal Court, which has concurrent jurisdiction with provincial superior courts but is the usual forum because its judgments apply across Canada. Remedies include injunctions, damages or an accounting of profits, and delivery up. In Nova Chemicals Corp. v. Dow Chemical Co., 2022 SCC 43, the Supreme Court upheld an accounting of profits that included "springboard" profits earned after expiry because of the head start the infringement gave.
Under s. 55.01, no remedy may be awarded for infringement committed more than six years before the action began. Defendants commonly counterclaim for invalidity, and anyone may also bring an impeachment action or request re-examination at CIPO. Our IP litigation page explains Federal Court practice in more detail.
Section 55(2) also allows a patentee to claim reasonable compensation for acts committed after the application was laid open to the public and before grant. That makes early monitoring of competitors worthwhile even while an application is pending. Before suing, a patentee should confirm title and any recorded licences, check that all maintenance fees were paid, review the prosecution history for statements that could narrow the claims, and assess the validity risk that a counterclaim will bring. A defendant should preserve documents, map the claims element by element, and look for prior art and prior-use defences early.
| Route | Who uses it | Key feature |
|---|---|---|
| Infringement action | Patentee or exclusive licensee | Injunction, damages or accounting of profits |
| Impeachment action | Any interested person | Declaration that the patent is invalid |
| Re-examination | Any person, at CIPO | Administrative review based on prior art |
| PM(NOC) action | Innovator against generic | 24-month stay on the notice of compliance |
How TRW & Co helps
We advise on Canadian patent law for technology companies, life sciences businesses and investors. Our work covers patent strategy and ownership, licensing and collaboration agreements, IP diligence on acquisitions and financings, and the commercial side of PM(NOC) and data protection planning. We coordinate with registered Canadian patent agents for prosecution before CIPO, and with litigation counsel licensed in the relevant jurisdiction where a step requires it. We also help businesses connect their patent position with life sciences regulation, technology transactions and M&A. This page is general information, not legal advice. To discuss a patent question, contact us.
Frequently asked questions
How long does a Canadian patent last?
For applications filed on or after 1 October 1989, the term is 20 years from the filing date under s. 44 of the Patent Act, provided maintenance fees are paid. The term can be lengthened by an additional term for unreasonable CIPO delay under s. 46.1, and drug patents may also qualify for a certificate of supplementary protection of up to two years.
Can I still patent an invention I have already disclosed?
Possibly. Section 28.2 gives a one-year grace period for disclosures made by the applicant or by people who obtained the information from the applicant. Disclosures by unrelated third parties are still prior art. Many foreign patent offices offer no comparable grace period, so a disclosure can still destroy rights outside Canada.
Are software and AI inventions patentable in Canada?
They can be. The claims must define more than a mere scientific principle or abstract theorem, which s. 27(8) excludes. CIPO looks at what the claimed invention actually contributes. Claims that tie an algorithm to a concrete technical solution are more likely to be allowed than claims to the algorithm as such.
What happens when a generic company challenges a drug patent?
Under the PM(NOC) Regulations, the generic serves a notice of allegation. The innovator has 45 days to sue in the Federal Court. Bringing the action usually prevents Health Canada from issuing the generic's notice of compliance for up to 24 months while the court decides infringement and validity.
Are communications with a patent agent privileged?
Yes, if the conditions in s. 16.1 of the Patent Act are met: the communication is between a patent agent and the client, is intended to be confidential, and is made to seek or give advice on matters the agent is authorized to handle. The privilege applies in civil, criminal and administrative proceedings.
Sources
- Patent Act (R.S.C. 1985, c. P-4), consolidated text
- Patent Rules (SOR/2019-251)
- Patented Medicines (Notice of Compliance) Regulations (SOR/93-133)
- Food and Drug Regulations (C.R.C., c. 870), s. C.08.004.1
- AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36
- Supreme Court of Canada, Case in Brief: Nova Chemicals Corp. v. Dow Chemical Co., 2022 SCC 43
General information only, not legal advice. References to statutes, courts and authorities describe published law and practice at the date shown.